Ra Capital Management, L.P. Acquires 1,483 Shares of Hemab Therapeutics (NASDAQ:COAG) Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. bought 1,483 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average cost of $24.98 per share, for a total transaction of $37,045.34. Following the completion of the purchase, the insider owned 6,325,914 shares of the company’s stock, valued at $158,021,331.72. This represents a 0.02% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.81 per share, for a total transaction of $989,149.89.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Trading Up 3.6%

COAG opened at $25.90 on Wednesday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Saturday.